Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 in relapsed or refractory esophagogastric malignancies
NCT02013154Phase 1Completed
- Sponsor
- Leap Therapeutics, Inc.
- Start
- May 2014
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial of sirexatamab in esophageal cancer, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Leap Therapeutics, Inc. Started May 2014; status: completed.
02
Drugs
sirexatamab
03
Conditions
esophageal cancergastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02013154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013154.